Larotrectinib for TRK Gene Fusion-positive Cancer: Patient & Caregiver Survey Now Available

The Canadian Cancer Survivor Network, in participation with six fellow Canadian patient groups have developed a new patient & caregiver survey.

The purpose of the survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives from patients and caregivers who are managing TRK gene fusion–positive cancers. This is in order to complete a patient evidence submission for a new targeted medication for TRK gene fusion–positive cancers called Larotrectinib.

If you are a patient or caregiver dealing with one of the following cancers, or another cancer affected by the TRK Fusion Gene, you may be eligible for the survey.

  • colorectal cancer
  • lung cancer
  • thyroid cancer
  • sarcoma
  • infantile fibrosarcoma
  • congenital nephroma

If you aren’t sure about your eligibility or have questions about this survey, please don’t hesitate to email us at

Take the survey here.